Mimi Cho, MD
Dermatology · Edina, MNNPI 1063449957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Merz North America, Inc. at 28.8% of the total. Reporting peaked in 2019 at $673 and has fallen 72.0% since, to $189 in 2025.
Across 75 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$551
- Pfizer$233
- Regeneron Healthcare Solutions, Inc.$138
- Sanofi$136
- LEO Pharma Inc.$88
- Incyte Corporation$69
- plus $702 from 19 others
What the payments were for
- Speaking & faculty fees$1257%
- Food & beverage$1,76292%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 4 | $551 |
| Pfizer | 8 | $233 |
| Regeneron Healthcare Solutions, Inc. | 8 | $138 |
| Sanofi | 3 | $136 |
| LEO Pharma Inc. | 6 | $88 |
| Incyte Corporation | 4 | $69 |
| Johnson & Johnson | 4 | $69 |
| Amgen | 4 | $68 |
| Dermavant Sciences, Inc. | 4 | $66 |
| Galderma Laboratories, L.p. | 4 | $55 |
| AbbVie | 3 | $51 |
| Lilly USA, LLC | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| UCB, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $37 |
| Novartis | 2 | $35 |
| Arcutis Biotherapeutics, Inc. | 2 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $32 |
| Smith+Nephew | 2 | $27 |
| Blueprint Medicines Corporation | 1 | $26 |
| DUSA Pharmaceuticals, Inc. | 1 | $24 |
| Biofrontera Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
| Biocon Biologics Inc | 1 | $13 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$125
How this compares
$1,917 in reported general payments places this provider in the 85th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $102,481 |
| Dupixent SyringeDupilumab | 12 | $45,833 |
| OpzeluraRuxolitinib Phosphate | 15 | $29,389 |
| Clobetasol Propionate | 213 | $7,222 |
| Metronidazole | 64 | $3,484 |
| Tretinoin | 32 | $2,346 |
| Tacrolimus | 19 | $1,670 |
| Ketoconazole | 88 | $1,650 |
| Clindamycin Phosphate | 34 | $1,517 |
| Hydroxychloroquine Sulfate | 13 | $982 |
| Doxycycline Hyclate | 29 | $967 |
| Desonide | 33 | $848 |
| Ciclopirox | 28 | $678 |
| ValacyclovirValacyclovir Hcl | 32 | $629 |
| Finasteride | 49 | $566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $69 | $29,38915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 273 dermatology providers in Minnesota.
Other dermatology in Edina
- Marie BridenEdina$2K
- Arthur IdeEdina$1K
- Michelle BussmannEdina$1K
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Todd SeelhammerSaint Paul$63K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.